<table className="table"><caption><p>First-Line and Salvage Treatment for <i>Helicobacter pylori</i> Infection</p></caption><thead><tr><th colSpan="1" rowSpan="1"><p>Treatment Regimen<sup>a</sup></p></th><th colSpan="1" rowSpan="1"><p>Comments/Indications</p></th></tr><tr><th colSpan="2" rowSpan="1"><p>First-Line Treatment</p></th></tr></thead><tbody><tr className="group_1-1 row-odd"><td colSpan="1" rowSpan="1"><p><b>Optimized bismuth quadruple therapy</b></p><p>PPI, bismuth subcitrate or subsalicylate, tetracycline, metronidazole</p></td><td colSpan="1" rowSpan="1"><p>May also be used for patients with a penicillin allergy</p></td></tr><tr className="group_1-2 row-even"><td colSpan="1" rowSpan="1"><p><b>Rifabutin triple therapy</b></p><p>Omeprazole, amoxicillin, rifabutin</p></td><td colSpan="1" rowSpan="1"><p>Alternative to bismuth quadruple therapy</p></td></tr><tr className="group_1-3 row-odd"><td colSpan="1" rowSpan="1"><p><b>PCAB dual therapy</b></p><p>Vonoprazan, amoxicillin</p></td><td colSpan="1" rowSpan="1"><p>Alternative to bismuth quadruple therapy</p></td></tr><tr className="group_1-4 row-even"><td colSpan="1" rowSpan="1"><p><b>PCAB-clarithromycin triple therapy</b></p><p>Vonoprazan, clarithromycin, amoxicillin</p></td><td colSpan="1" rowSpan="1"><p>Avoid in patients with a history of macrolide exposure</p><p>Should generally be reserved for patients with documented clarithromycin sensitivity</p></td></tr><tr><th colSpan="2" rowSpan="1"><p>Salvage Treatment</p></th></tr><tr className="group_2-1 row-odd"><td colSpan="1" rowSpan="1"><p><b>Optimized bismuth quadruple therapy</b></p><p>PPI, bismuth subcitrate or subsalicylate, tetracycline, metronidazole</p></td><td colSpan="1" rowSpan="1"><p>If previous therapy was not bismuth quadruple therapy</p><p>Failure of clarithromycin-based therapy</p></td></tr><tr className="group_2-2 row-even"><td colSpan="1" rowSpan="1"><p><b>Rifabutin triple therapy</b></p><p>PPI, amoxicillin, rifabutin</p></td><td colSpan="1" rowSpan="1"><p>Failure of bismuth-based quadruple therapy</p></td></tr><tr className="group_2-3 row-odd"><td colSpan="1" rowSpan="1"><p><b>Levofloxacin triple therapy</b></p><p>PPI, levofloxacin, amoxicillin</p></td><td colSpan="1" rowSpan="1"><p>Proven levofloxacin-sensitive <i>Helicobacter pylori</i></p><p>Failure of optimized bismuth quadruple therapy or rifabutin triple therapy</p><p>Nonavailability of bismuth quadruple therapy or rifabutin triple therapy</p></td></tr><tr className="group_2-4 row-even"><td colSpan="1" rowSpan="1"><p><b>PCAB-clarithromycin triple therapy</b></p><p>Vonoprazan, clarithromycin, amoxicillin</p></td><td colSpan="1" rowSpan="1"><p>Proven clarithromycin-sensitive <i>H. pylori</i></p><p>Failure of optimized bismuth quadruple therapy or rifabutin triple therapy</p><p>Nonavailability of bismuth quadruple therapy or rifabutin triple therapy</p></td></tr></tbody></table>